Novel insights into the pathobiology of the vascular access - Do they translate into improved care?

Blood Purification

Volumn 29, Issue 2, 2010, Pages 216-229

  Diskin, Charles J ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Drug therapy; Hemodialysis; Renal failure; Thrombosis; Vascular access

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FLUINDOSTATIN; GLYCERYL TRINITRATE; ICOSAPENTAENOIC ACID; PENTOXIFYLLINE; RECOMBINANT ERYTHROPOIETIN; SIMVASTATIN; THROMBOXANE SYNTHASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; BIOTECHNOLOGY; BLOOD CLOTTING; CELL MIGRATION; GLYCOCALYX; HEMODIALYSIS; HEMOSTASIS; HUMAN; LOW DRUG DOSE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; STENOSIS; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR ACCESS; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ARTERIOVENOUS SHUNT, SURGICAL; CALCIUM CHANNEL BLOCKERS; CATHETERS, INDWELLING; CELL MOVEMENT; CONSTRICTION, PATHOLOGIC; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; EQUIPMENT FAILURE; FORECASTING; HEMORHEOLOGY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERPLASIA; MODELS, CARDIOVASCULAR; NITRIC OXIDE; PENTOXIFYLLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; SEPSIS; THROMBOSIS; TUNICA INTIMA; VASODILATION;

EID: 77749320431     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245650     Document Type: Review

References (167)

1. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI, DAC Study Group: Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 2009; 360: 2191-2201.
2. Lok CE: Antiplatelet therapy and vascularaccess patency. N Engl J Med 2009; 360: 2240-2242.
3. Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, Weerts CA: Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med 1979; 301: 577-579.
4. Busk M, Mertz H, Espersen GT, Rasmussen K, Maeng M: Effects of pentoxifylline on the vascular response to injury after angioplasty in rabbit iliac arteries. Basic Res Cardiol 2008; 103: 257-264.
5. Dumas A: The Count of Monte Cristo. New York, Cuneo Press, 1936, chapt 17: The Leaned Italian.
6. Aristotle: De Partibus Animalium (transl by W. Ogle). London, Keegan Paul, Trench & Co, 1882, book ii, 4, p 31.
7. Lister J: Notice of further research on the coagulation of blood. Edinburgh Medical Journal 1859, December. The Collected Papers of Joseph Baron Lister. Oxford, Clarendon Press, 1909, pp 105-108.
8. Lister J: On the coagulation of blood. Edinburgh Medical Journal 1863, June. The Collected Papers of Joseph Baron Lister. Oxford, Clarendon Press, 1909, pp 109-134.
9. Boyd SJ, Dennis MB, Nogami RT, Cole JJ, Scribner BH: Prophylactic coumadin and AV cannula function. J Appl Physiol 1974; 37: 6-7.
10. Wing AJ, Curtis JR, De Wardener HE: Reduction of clotting of Scribner shunts by long term anticoagulation. Br Med J 1967; 3: 143-145.
11. Biggers JA, Remmers AR, Glassford DM, et al: The risk of anticoagulation in hemodialysis patients. Nephron 1977; 18: 109-113.
12. Leonard A, Shapiro FL: Subdural hematoma in regularly hemodialyzed patients. Ann Intern Med 1975; 82: 650-658.
13. Brautbar N, Menz CL, Winston MA, Shinan-berger JH: Retroperitoneal bleeding in hemodialyzed patients: a cause for morbidity and mortality. JAMA 1978; 239: 1530-1532.
14. Diskin CJ, Stokes TJ, Thomas SG, Ravis W, Lock S, Thomas J, Panus LW, Dansby L, Carter T: An analysis of the effect of routine medications on hemodialysis vascular access survival. Nephron 1998; 78: 365-368.
15. Diskin CJ: Observations on therapeutic drug use and hemodialysis vascular access failure. Am J Kidney Dis 2003; 41: 901.
16. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW, Dialysis Outcomes and Practice Patterns Study group: Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2002; 40: 1255-1263.
17. Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, et al: Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002; 13: 2331-2337.
18. Moncada S, Gryglewski R, Bunting S, Vane JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665.
19. Jenkins AM, Buist TA, Glover SD: Medium term follow-up of forty autogenous vein and forty polytetrafluoroethylene grafts for vascular access. Surgery 1980; 88: 667-672.
20. Glasham RW, Walker F: A histologic examination of Quinton/Scribner shunts. Br J Surg 1968; 55: 189-192.
21. Roedersheimer MLR, Deweese JA: Effect of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery 1982; 92: 1016-1026.
22. McCann RL, Hagen PO, Fuchs JC: Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts. Ann Surg 1980; 191: 238-243.
23. Friedman RJ, Stemerman MB, Wenz B, Moore S: The effects of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. J Clin Invest 1977; 60: 1191-1201.
24. Hasegawa T, Elder SJ, Bragg-Gresham JL, Pisoni RL, Yamazaki S, Akizawa T, Jadoul M, Hugh RC, Port FK, Fukuhara S: Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 2008; 3: 1373-1378.
25. Van der Ouderaa FJ, Buytenhek M, Nugteren DH, Van Dorp DA: Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. Eur J Biochem 1980; 109: 1-8.
26. Graham LM, Brother TE, Vincent CK, et al: The effect of duration of acetylsalicylic acid administration on patency and anastomotic hyperplasia of PTFE grafts (abstract). Am Soc Artif Int Org 1989; 35: 83.
27. Endean ED, Boorstein JM, Hees PL, Cronenwett JL: Effect of thromboxane synthetase inhibition on canine autogenous vein grafts. J Surg Res 1986; 40: 297-304.
28. Yevzlin AS, Conley EL, Sanchez RJ, Young HN, Becker BN: Vascular access outcomes and medication use: a USRDS study. Semin Dial 2006; 19: 535-539.
29. Nicolucci A: Aspirin for primary prevention of cardiovascular events in diabetes: still an open question. JAMA 2008; 300: 2180-2181.
30. Woods RL, Tonkin AM, Nelson MR, Britt HC, Reid CM: Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes? Med J Aust 2009; 190: 614-619.
31. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R, Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, Royal College of Physicians Edinburgh: The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840. DOI: 10.1136/bmj.a1840.
32. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators: Lowdose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134-2141.
33. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM: Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994; 45: 1477-1483.
34. Endean ED, Boorstein JM, Hees PL, Cronenwett JL: Effect of thromboxane synthetase inhibition on canine autogenous vein grafts. J Surg Res 1986; 40: 297-304.
35. Andreucci VE, Fissell RB, Bragg-Gresham JL, Ethier J, Greenwood R, Pauly M, Wizemann V, Port FK: Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis 2004; 44(suppl 2):61-67.
36. Puskar D, Pasini J, Savić I, Bedalov G, Sonicki Z: Survival of primary arteriovenous fistula in 463 patients on chronic hemodialysis. Croat Med J 2002; 43: 306-311.
37. Tsuchikane E, Suzuki T, Katoh O, Suzuki T: Examination of anti-intima hyperplastic effect on cilostazol-eluting stent in a porcine model. J Invas Cardiol 2007; 19: 109-112.
38. Min PK, Jung JH, Ko YG, Choi D, Jang Y, Shim WH: Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. Circ J 2007; 71: 1685-1690.
39. Bhatt DL, Fox KA, Hacke W, et al: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
40. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
41. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625-628.
42. Bhatt DL, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J 2000; 140: 67-73.
43. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W, Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events Investigators: Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004; 35: 528-532.
44. Dyerberg J, Bang HO, Stofferson E: Eicosapentaenoic acid and prevention of thrombosis. Lancet 1978;ii:117.
45. Rylance PB, Gordge MP, Saynor R, Parson V, Weston MJ: Fish oil modifies lipids and reduces platelet aggregability in hemodialysis patients. Nephron 1986; 43: 196-202.
46. Landymore RW, MacAulay MA, Cooper JH: Effects of cod liver oil on intimal hyperplasia in vein grafts used for arterial bypass. Can J Surg 1986; 29: 129-131.
47. Landymore RW, Kinley CE, Cooper, et al: Cod liver oil for prevention of intimal hyperplasia of autogenous vein grafts used for arterial bypass. J Thorac Cardiovasc Surg 1985; 89: 351-357.
48. Cahill PD, Sarris GE, Cooper AD, et al: Inhibition of vein graft intimal thickening by eicosapentaenoic acid: reduced thromboxane production without change in lipoprotein levels or low density lipoprotein density. J Vasc Surg 1988; 7: 108-118.
49. Diskin CJ, Thomas CE, Zellner CP, Lock S, Tanja J: Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron 1990; 55: 445-447.
50. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME: Prophylaxis of hemodialysis graft thrombosis with fish oil: doubleblind, randomized, prospective trial. Am Soc Nephrol 2002; 13: 184-190.
51. Kaufman JS, O'Connor TZ, Zhang ZH, Cronin RE, Fiore LD, Ganz MB: Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis, J Am Soc Nephrol 2003; 14: 2313-2321.
52. Trimarchi H, Young P, Forrester M, Schropp J, Pereyra H, Freixas E: Clopidogrel diminishes hemodialysis access graft thrombosis. Nephron Clin Pract 2006; 102:c128-c132.
53. Janicki K, Pietura R, Bojarska-Szmygin A, Gieryng J, Orłowska A, Janicka L: Preventive administration of clopidogrel after restoring patency of acute dialysis fistula with surgical thrombectomy. Ann Univ Mariae Curie Sklodowska (Med) 2003; 58: 211-214.
54. Bowden RG, Wilson RL, Gentile M, Ounpra-seuth S, Moore P, Leutholtz BC: Effects of omega-3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. J Ren Nutr 2007; 17: 126-131.
55. Osborn G, Escofet X, Da Silva A: Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev 2008; 4:CD002786.
56. Chan KE, Lazarus JM, Thadhani R, Hakim RM: Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20: 872-881.
57. Diskin CJ, Stokes TJ Jr, Pennell AT: Pharmacologic intervention to prevent hemodialysis vascular access thrombosis. Nephron 1993; 64: 1-26.
58. Diskin CJ, Stokes TJ, Pennell A: Pharmacologic intervention to prevent intimal hyperplasia; in Henry M, Fergusen R (eds): Vascular Access III. Chicago, Prentice Press, 1993, chapt 3, pp 41-86.
59. Jaffredo T, Nottingham W, Liddiard K, Bollerot K, Pouget C, de Bruijn M: From hemangioblast to hematopoietic stem cell: an endothelial connection? Exp Hematol 2005; 33: 1029-1040.
60. Dieterlen-Lièvre F, Pouget C, Bollérot K, Jaffredo T: Are intra-aortic hemopoietic cells derived from endothelial cells during ontogeny? Trends Cardiovasc Med 2006; 16: 128-139.
61. Boos CJ, Blann AD, Lip GY: Assessment of endothelial damage/dysfunction: a focus on circulating endothelial cells. Methods Mol Med 2007; 139: 211-224.
62. Ryan US, Ryan JW: The ultrastructural basis of endothelial surface functions. Biorheology 1984; 21: 155-170.
63. Ryan US: Immunologic properties of endothelial cells. ASAIO J 1985; 8: 58-64.
64. Becker BF, Heindl B, Kupatt C, Zahler S: Endothelial function and hemostasis. Z Kardiol 2000; 89: 160-167.
65. Bian K, Doursout MF, Murad F: Vascular system: role of nitric oxide in cardiovascular diseases. J Clin Hypertens (Greenwich) 2008; 10: 304-310.
66. Lam CF, Peterson TE, Richardson DM, Croatt AJ, d'Uscio LV, Nath KA, Katusic ZS: Increased blood flow causes coordinated upregulation of arterial eNOS and biosynthesis of tetrahydrobiopterin. Am J Physiol Heart Circ Physiol 2006; 290:H786-H793.
67. Hayashi K, Mori K, Miyazaki H: Biomechanical response of femoral vein to chronic elevation of blood pressure in rabbits. Am J Physiol Heart Circ Physiol 2003; 284:H511-H518.
68. Geisterfer AA, Peach MJ, Owens GK: Angiotensin produces hypertrophy, not hyperplasia of aortic smooth muscle cells. Circ Res 1988; 62: 749-756.
69. Powell JS, Rouge M, Muller RK, Baumgartener HR: Cilazapril suppresses myointimal hyperplasia after vascular injury: effects on growth factor induction in vascular smooth muscle cells. Basic Res Cardiol 1991; 86(suppl 1):65-74.
70. Capron L, Heudes D, Chajara A, Bruneval P: Effect of rampril, a converting enzyme inhibitor on the response of rat thoracic aorta to injury with a balloon catheter. J Cardiovasc Pharmacol 1991; 18: 207-211.
71. O'Donohoe MK, Schwartz LB, Radic ZS, Mikat EM: Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts. Ann Surg 1991; 214: 727-732.
72. Jahnke T, Karbe U, Schäfer FK, Bolte H, Heuer G, Rector L, Brossmann J, Heller M, Müller-Hülsbeck S: Characterization of a new double-injury restenosis model in the rat aorta. J Endovasc Ther 2005; 12: 318-331.
73. van der Harst P, Groenewegen HC, Roks AJ, Buikema H, Zijlstra F, van Gilst WH, de Smet BJ: Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat. Coron Artery Dis 2008; 19: 47-53.
74. Nishimura H, Tsuji H, Masuda H, Nakagawa K, Nakahara Y, Kitamura H, Kasahara T, Sugano T, Yoshizumi M, Sawada S, Nakagawa M: Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997; 77: 1189-1195.
75. Katoh M, Egashira K, Mitsui T, Chishima S, Takeshita A, Narita H: Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol 2000; 32: 73-83.
76. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001.
77. Kubo-Inoue M, Egashira K, Usui M, Takemoto M, Ohtani K, Katoh M, Shimokawa H, Takeshita A: Long-term inhibition of nitric oxide synthesis increases arterial thrombogenicity in rat carotid artery. Am J Physiol Heart Circ Physiol 2002; 282:H1478-H1484.
78. Busk M, Mertz H, Espersen GT, Rasmussen K, Maeng M: Effects of pentoxifylline on the vascular response to injury after angioplasty in rabbit iliac arteries. Basic Res Cardiol 2008; 103: 257-264.
79. Bakken AM, Galaria II, Agerstrand C, Saad WE, Surowiec SM, Singh MJ, Rhodes JM, Lee D, Patel NC, Illig KA, Waldman DL, Davies MG: Percutaneous therapy to maintain dialysis access successfully prolongs functional duration after primary failure. Ann Vasc Surg 2007; 21: 474-480.
80. Diskin CJ: Pharmacologic intervention to prevent hemodialysis vascular access thrombosis: the next generation of treatment? Kidney Int 2005; 67: 2505.
81. Masaki T, Rathi R, Zentner G, Leypoldt JK, Mohammad SF, Burns GL, Li L, Zhuplatov S, Chirananthavat T, Kim SJ, Kern S, Holman J, Kim SW, Cheung AK, Masaki T, Rathi R, Zentner G, Leypoldt JK, Mohammad SF, Burns GL, Li L, Zhuplatov S, Chirananthavat T, Kim SJ, Kern S, Holman J, Kim SW, Cheung AK: Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int 2004; 66: 2061-2069.
82. Schuman E, Babu J: Sirolimus-loaded polyurethane graft for hemodialysis access in sheep. Vascular 2008; 16: 269-274.
83. Camenzind E, Steg PG, Wijns W: Stent thrombosis late after implantation of firstgeneration drug-eluting stents: a cause for concern. Circulation 2007; 115: 1440-1455.
84. Ota T, Umeda H, Yokota S, Miyata S, Takamura A, Sugino S, Hayashi K, Ishiki R, Takeichi Y, Iwase M, Inagaki H, Murohara T: Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation. Am Heart J 2009; 158: 92-98.
85. Chan MR, Young HN, Yevzlin AS: The effect of in-stent restenosis on hemodialysis access patency. Hemodial Int 2009; 13: 250-256.
86. Yevzlin A, Asif A: Stent placement in hemodialysis access: historical lessons, the state of the art and future directions. Clin J Am Soc Nephrol 2009; 4: 996-1008.
87. Misra S, Bonan R, Pflederer T, Roy-Chaudhury P, BRAVO I Investigators: BRAVO I: a pilot study of vascular brachytherapy in polytetrafluoroethylene dialysis access grafts. Kidney Int 2006; 70: 2006-2013.
88. Radomski MW, Palmer RMJ, Moncada S: The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987; 148: 1482-1489.
89. Luscher TF, Diederich D, Siebenmann R, Lehman K: Difference between endothelium dependent relaxation in arterial and venous coronary artery bypass graft. N Engl J Med 1988; 319: 462-467.
90. Komri K, Gloviczki P, Bourchier RG, Miller VM, et al: Endothelium dependent vasorelaxations in response to aggregating platelets are impaired in reverse vein grafts. J Vasc Surg 1990; 12: 139-147.
91. Moncada S, Palmer RMJ, Higgs EA: Biosynthesis of nitric oxide from L-arginine. Nature 1987; 327: 524-526.
92. Drexler H, Zeiher AM, Meinzer K, Just H: Correction of endothelial dysfunction in microcirculation of hypercholesterolemic patients by L-arginine. Lancet 1991; 338: 1546-1550.
93. Sajgure A, Choudhury A, Ahmed Z, Choudhury D: Angiotensin converting enzyme inhibitors maintain polytetrafluoroethylene graft patency. Nephrol Dial Transplant 2007; 22: 1390-1398.
94. Gradzki R, Dhingra RK, Port FK, Roys E, Weitzel WF, Messana JM: Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis 2001; 38: 1240-1244.
95. Diskin CJ: Notes on angiotensin inhibition and vascular access survival: time for randomized controlled trials. Nephrol Dial Transplant 2006; 21: 823.
96. Clozel M, Kuhn H, Hefti F: Effects of angiotensin converting enzyme inhibitors and hydralazine on endothelial function in the spontaneous hypertensive rat. Hypertension 1990; 16: 541-543.
97. Habib JB, Bossaller C, Wells S, et al: Preservation of endothelium dependent relaxation factor in cholesterol fed rabbits by treating with calcium channel blocker PN 200110. Circ Res 1986; 58: 305-309.
98. Long CJ, Stone TW: The release of endothelium relaxation factor is calcium dependent. Blood Vessels 1985; 22: 205-208.
99. Schulman IH, Zachariah M, Raij L: Calcium channel blockers, endothelial dysfunction, and combination therapy. Aging Clin Exp Res 2005; 17(4 suppl):40-45.
100. Aslam S, Santha T, Leone A, Wilcox C: Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int 2006; 70: 2109-2115.
101. Simon AC, Pithois-Merli I, Levenson J: Physiopharmacologic approach to the mechanical factors of hypertension in the atherosclerotic process. J Hum Hypertens 1991; 5(suppl 1):15-21.
102. El-Sanadiki MN, Cross KS, Murray JJ, Schuman RW, et al: Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment. Ann Surg 1990; 212: 87-96.
103. Nakao J, Ito H, Ooyama Y, Chang WC, Murota S: Calcium dependency of aortic smooth muscle migration induced by 12-L-hydroxy-5,8,10,14- eicosatetraenoic acid: effect of A23187, nicardipine and trifluoperazine. Atherosclerosis 1983; 46: 309-319.
104. 2+ responses and chemotaxis in cultured human vascular smooth muscle cells. Br J Pharmacol 2005; 145: 811-817.
105. Shima E, Katsube M, Kato T, Kitagawa M, Hato F, Hino M, Takahashi T, Fujita H, Kitagawa S: Calcium channel blockers suppress cytokine-induced activation of human neutrophils. Am J Hypertens 2008; 21: 78-84.
106. Matsumori A, Nunokawa Y, Sasayama S: Nifedipine inhibits activation of transcription factor NF-kappaB. Life Sci 2000; 67: 2655-2661.
107. Fang CC, Yen CJ, Chen YM, Chu TS, Lin MT, Yang JY, Tsai TJ: Diltiazem suppresses collagen synthesis and IL-1beta-induced TGF-beta1 production on human peritoneal mesothelial cells. Nephrol Dial Transplant 2006; 21: 1340-1347.
108. Min SK, Kenagy RD, Clowes AW: Induction of vascular atrophy as a novel approach to treating restenosis: a review. J Vasc Surg 2008; 47: 662-670.
109. Takeuchi K, Itoh H, Yonemitsu Y, Matsumoto T, Kume M, Komori K, Maehara Y: In vivo reduction of the nuclear factor-kappaB activity using synthetic cis-element decoy oligonucleotides suppresses intimal hyperplasia in the injured carotid arteries in rabbits. Surg Today 2007; 37: 575-583.
110. Razuvaev A, Henderson B, Girnita L, Larsson O, Axelson M, Hedin U, Roy J: The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling. J Vasc Surg 2007; 46: 108-115.
111. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB: Is systemic heparin a risk fac-tor for catheter-related sepsis in dialysis patients? An evaluation of various biofilm and traditional risk factors. Nephron Clin Pract 2007; 107:c128-c132.
112. Klevens RM, Edwards JR, Andrus ML, Peterson KD, Dudeck MA, Horan TC: NHSN participants in outpatient dialysis surveillance. Dialysis surveillance report: National Healthcare Safety Network (NHSN) - data summary for 2006. Semin Dial 2008; 21: 24-28.
113. Perunicic-Pekovic G, Pljesa S, Rasic-Milutinovic Z, Stankovic S, Ilic M, Maletic R: Inflammatory cytokines and malnutrition as related to risk for cardiovascular disease in hemodialysis patients. Can J Physiol Pharmacol 2008; 86: 205-209.
114. Narayanan S: Inhibition of in vitro platelet inhibition and release and fibrinolysis. Ann Clin Lab Sci 1989; 19: 260-265.
115. Parker MT, Turrentine MA, Johnson GS: Von Willebrand factor in lysates of washed canine platelet. Am J Vet Res 1991; 52: 119-125.
116. Huang ZS, Lee TK: Comparison of in vitro platelet aggregation and its inhibition by three antithrombotic drugs between human and guinea pig. Proc Natl Sci Counc Rep China 1991; 15: 8-14.
117. Raithel D: Prevention of re-occlusion after prosthetic bypass operations in the femoropopliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid. Vasc Surg 1987; 21: 208-214.
118. Lucas M: Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six month randomized follow-up study. Angiology 1984; 35: 443-450.
119. Weithman KU, Just M, Schlotte V, Seiffge D: Stimulatory effects of vascular prostaglandins on the antiaggregatory activities of pentoxifylline-acetylsalicylic acid combinations in vitro. Vasa 1989; 18: 273-276.
120. Lenoble-Giovannangeli M: New aspects of the pharmacology of pentoxifylline. J Mal Vasc 1989; 14(suppl A):35-41.
121. Schroer RH: Antithrombotic potential of pentoxifylline: a hemorheologically active drug. Angiology 1985; 36: 387-398.
122. Weithman KU: Reduced platelet aggregation by pentoxifylline stimulated prostacyclin release. Vasa 1981; 10: 249-252.
123. Herskovits E, Famulari A, Tamaroff L, Gonzalez AM, et al: Prevention treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants. Eur Neurol 1985; 24: 73-81.
124. Han J, Thompson P, Beutler B: Dexamethasone and pentoxifylline inhibit endotoxininduced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391-394.
125. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB: Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker? J Nephrol 2007; 20: 410-416.
126. Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ: Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int 2006; 69: 1410-1415.
127. Maiti R, Agrawal NK, Dash D, Pandey BL: Effect of pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vasc Pharmacol 2007; 47: 118-124.
128. Fernandes JL, de Oliveira RT, Mamoni RL, Coelho OR, Nicolau JC, Blotta MH, Serrano CV Jr: Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease - a randomized placebo-controlled study. Atherosclerosis 2008; 196: 434-442.
129. de Albuquerque RM, Virgini-Magalhaes CE, Lencastre Sicuro F, Bottino DA, Bouskela E: Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology 2008; 59: 549-558.
130. Stinghen AE, Gonçalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, Pecoits-Filho R: Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract 2009; 111:c117-c126.
131. Radmilovic A, Boric Z, Naumovic T, Stamenkovic M, Musikic P: Shunt thrombosis prevention in hemodialysis patients - double blind, randomized study: pentoxifylline vs placebo. Angiology 1987; 38: 499-506.
132. Busk M, Mertz H, Espersen GT, Rasmussen K, Maeng M: Effects of pentoxifylline on the vascular response to injury after angioplasty in rabbit iliac arteries. Basic Res Cardiol 2008; 103: 257-264.
133. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB: Beyond anemia: the clinical impact of the physiologic effects of erythropoietin. Semin Dial 2008; 21: 447-454.
134. Fried W, Barone-Varelas J, Barone T, Anagnostou A: Effect of angiotensin infusion on extrarenal erythropoietin production. J Lab Clin Med 1982; 99: 520-525.
135. Navarro JF, Macia ML, Mora-Fernandez C, Gallego E, Chahin J, Mendez ML, del Castillo N, Rivero A, Garcia J: Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients. Adv Perit Dial 1997; 13: 257-259.
136. Du J, Peng T, Scheidegger KJ, Delafontaine P: Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler Thromb Vasc Biol 1999; 19: 2119-2126.
137. Reddy MK, Vasir JK, Hegde GV, Joshi SS, Labhasetwar V: Erythropoietin induces excessive neointima formation: a study in a rat carotid artery model of vascular injury. J Cardiovasc Pharmacol Ther 2007; 12: 237-247.
138. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H: Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353: 782-792.
139. Diskin CJ, Stokes TJ, Dansby L, Radcliff L, Carter T: A hypothesis: can erythropoietin administration affect the severity of retinopathy in diabetic patients with renal failure? Am J Med Sci 2007; 334: 260-264.
140. Diskin CJ: Erythropoietin and retinopathy: the beginning of an understanding. Br J Ophthalmol 2008; 92: 574.
141. Lee YK, Koo JR, Kim JK, Park II, Joo MH, Yoon JW, Noh JW, Vaziri ND: Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial. Am J Kidney Dis 2009; 53: 815-822.
142. Fairbanks KP, Witte LD, Goodman DS: Relationship between mevalonate and mitogenesis in human fibroblasts stimulated by platelet derived growth factor. J Biol Chem 1984; 259: 1546-1551.
143. Falke P, Mattiasson I, Stavenow L, Hood B: Effects of competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on human and bovine endothelial cells, fibroblasts, and smooth muscle cells in vitro. Pharmacol Toxicol 1989; 64: 173-176.
144. Gellman J, Ezekowitz MD, Sarembock IJ, Azrin MA, et al: Effect of lovastatin on intimal hyperplasia after balloon angioplasty: a study in a hypercholesterolemic rabbit. J Am Coll Cardiol 1991; 17: 251-259.
145. Turner NA, Aley PK, Hall KT, Warburton P, Galloway S, Midgley L, O'Regan DJ, Wood IC, Ball SG, Porter KE: Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. J Mol Cell Cardiol 2007; 43: 168-176.
146. Turner NA, Midgley L, O'Regan DJ, Porter KE: Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol 2007; 50: 458-461.
147. Magaraggia M, Marigo L, Pagnan A, Jori G, Visonà A: Porphyrin-photosensitized processes: their applications in the prevention of arterial restenosis. Cardiovasc Hematol Agents Med Chem 2007; 5: 278-288.
148. Barton J, Nielsen H, Rychnovsky S, Farooq M, Freischlag J, Grove R: Photopoint photodynamic therapy inhibits intimal hyperplasia in arteriovenous access grafts. Cardiovasc Radiat Med 2002; 3: 147-151.
149. Heckenkamp J, Mellander S, Fogelstrand P, Breuer S, Brunkwall J, Mattsson E: Photodynamic therapy reduces intimal hyperplasia in prosthetic vascular bypass grafts in a pig model. Eur J Vasc Endovasc Surg 2007; 34: 333-339.
150. Zhang H, Sunnarborg SW, McNaughton KK, Johns TG, Lee DC, Faber JE: Heparinbinding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling. Circ Res 2008; 102: 1225-1285.
151. Hirsch GM, Karnovsky MJ: Inhibition of vein graft intimal hyperplasia lesions in the rat by heparin. Am J Pathol 1991; 139: 581-587.
152. Danenberg HD, Grad E, Swaminathan RV, Chen Z, Seifert P, Szalai AJ, Lotan C, Simon DI, Edelman ER: Neointimal formation is reduced after arterial injury in human crp transgenic mice. Atherosclerosis 2008, E-pub ahead of print.
153. Seuter F, Bayer AG: Pharmacologic inhibition of experimental atherosclerosis. Z Kardiol 1989; 78(suppl 6):117-119.
154. Norman PE, House AK: Heparin reduces intimal hyperplasia seen in microvascular vein grafts. Aust NZ J Surg 1991; 61: 942-948.
155. Wight TN: Cell biology of arterial proteoglycans. Arteriosclerosis 1989; 9: 1-20.
156. Bassols A, Massague J: Transforming growth factor beat regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. J Biol Chem 1986; 263: 3039-3045.
157. Forrester JS, Fishbein M, Helfant R, Fagin J: A paradigm for restenosis based on cell biology: clues for the development of new therapies. J Am Coll Cardiol 1991; 17: 758-769.
158. Walsh DB, Zwolak RM, Mcdaniel MD, Scheinder JR, Cronenwett JL: Intragraft drug infusion as adjunct to balloon catheter for salvage of thrombosed infragenicular vein graft. J Vasc Surg 1990; 11: 753-759.
159. Wilson NV, Salisbury JR, Kakkar VV: Effect of low molecular heparin on intimal hyperplasia. Br J Surg 1991; 78: 1381-1383.
160. D'Ayala M, Smith RM, Martone C, Briggs W, Deitch JS, Wise L: The effect of systemic anticoagulation in patients undergoing angioaccess surgery. Ann Vasc Surg 2008; 22: 11-15.
161. Fu Y, Zhang Z, Zhang G, Liu Y, Cao Y, Yu J, Hu J, Yin X: Adenovirus-mediated gene transfer of tissue factor pathway inhibitor induces apoptosis in vascular smooth muscle cells. Apoptosis 2008; 13: 634-640.
162. Li Q, Zhang K, Jiang X, Sun T, Wu L, Zhou C, Chen S: Influence of human tissue factor pathway inhibitor gene transfection on neointima formation in vein grafts. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2008; 22: 354-358.
163. Hoel AW, Conte MS: Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass. Cardiovasc Drug Rev 2007; 25: 221-234.
164. Barceló SA, Hevelone ND, Lipsitz SR, Bandyk DF, Clowes AW, Moneta GL, Conte MS: Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis of midterm outcomes from the PREVENT III trial. J Vasc Surg 2007; 46: 1173-1179.
165. Magee MJ, Alexander JH, Hafley G, Ferguson TB Jr, Gibson CM, Harrington RA, Peterson ED, Califf RM, Kouchoukos NT, Herbert MA, Mack MJ, PREVENT IV Investigators: Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV. Ann Thorac Surg 2008; 85: 494-499.
166. Pearce CG, Najjar SF, Kapadia MR, Murar J, Eng J, Lyle B, Aalami OO, Jiang Q, Hrabie JA, Saavedra JE, Keefer LK, Kibbe MR: Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radic Biol Med 2008; 44: 73-81.
167. Boorstin DJ: The Discoverers. New York, Vintage Press, 1983.